Proton pump inhibitor (PPI) use is associated with incident chronic kidney disease (CKD), according to new findings. Lazarus and et al. studied the effects of PPIs in 10,484 participants of the Atherosclerosis Risk in Communities study, and found that twice-daily PPI dosing was associated with a higher risk of CKD than once-daily dosing. As PPIs are one of the most commonly used drugs worldwide, the researchers propose that future studies should investigate whether limiting PPI use will reduce the incidence of CKD.